Purpose. Macrolide susceptibility differs between subspecies in the Mycobacterium abscessus complex, likely due to differences in erm(41) sequevars. Patients with M. abscessus complex infection generally show poor clinical outcomes in response to antibiotic treatment. Here, the association between genotype and treatment outcome was investigated.
Methodology. We collected 69 isolates from 35 patients with non-cystic fibrosis bronchiectasis: 24 had M. abscessus complex lung disease and non-cystic fibrosis bronchiectasis, and 11 were colonized. Outcome analysis was performed in the 24 infected patients. Molecular analyses, including erm(41) and rrl sequencing, and variable-number tandem-repeat (VNTR) analysis of 69 isolates, from 24 infected and 11 colonized patients, were performed to elucidate the influence of genotype on antibiotic susceptibility.
Results. Among the 24 patients, 18 (14 infected with M. abscessus subsp. abscessus and 4 with M. abscessus subsp. massiliense) showed unfavourable outcomes; six (three infected with M. abscessus subsp. abscessus and three with M. abscessus subsp. massiliense) exhibited favourable outcomes. Patients with unfavourable outcomes showed acquired clarithromycin resistance (33.3 vs 0 %), mixed sequevars (38.9 vs 16.7 %) and differing VNTR patterns between initial and serial isolates (33.3 vs 16.7 %). In contrast, in the 11 colonized patients, M. abscessus subsp. abscessus C28 (sequevar 02) and M. abscessus subsp. massiliense were the most prevalent subspecies.
Conclusion. Patients infected with multiple sequevars and genotypes were more likely to exhibit treatment failure and/or recurrence. The precise identification of subspecies and analyses of mycobacterial characteristics may help to predict treatment outcomes in patients with M. abscessus complex lung disease.
GriffithDE,
AksamitT,
Brown-ElliottBA,
CatanzaroA,
DaleyC et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med2007; 175:367–416 [View Article][PubMed]
FlotoRA,
OlivierKN,
SaimanL,
DaleyCL,
HerrmannJL et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax2016; 71:88–90 [View Article][PubMed]
KohWJ,
JeonK,
LeeNY,
KimBJ,
KookYH et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus
. Am J Respir Crit Care Med2011; 183:405–410 [View Article][PubMed]
NashKA,
Brown-ElliottBA,
WallaceRJ.
A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae
. Antimicrob Agents Chemother2009; 53:1367–1376 [View Article][PubMed]
BastianS,
VezirisN,
RouxAL,
BrossierF,
GaillardJL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother2011; 55:775–781 [View Article][PubMed]
Brown-ElliottBA,
VasireddyS,
VasireddyR,
LakhiaevaE,
HowardST et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin 364 MICs. J Clin Microbiol2015; 365:1211–1215
ChristiansonS,
GriersonW,
KeinD,
TylerAD,
WolfeJ et al. Time-to-detection of inducible macrolide resistance in Mycobacterium abscessus subspecies and its association with the erm(41) sequevar. PLoS One2016; 11:e0158723 [View Article][PubMed]
KimSY,
ShinSJ,
JeongBH,
KohWJ.
Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. BMC Infect Dis2016; 16:207 [View Article][PubMed]
WallaceRJ,
MeierA,
BrownBA,
ZhangY,
SanderP et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus
. Antimicrob Agents Chemother1996; 40:1676–1681[PubMed]
ShallomSJ,
GardinaPJ,
MyersTG,
SebastianY,
ConvilleP et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. J Clin Microbiol2013; 51:2943–2949 [View Article][PubMed]
MougariF,
AmarsyR,
VezirisN,
BastianS,
BrossierF et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother2016; 71:2208–2212 [View Article][PubMed]
JeonK,
KwonOJ,
LeeNY,
KimBJ,
KookYH et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med2009; 180:896–902 [View Article][PubMed]
Clinical and Laboratory Standards InstituteSusceptibility testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, 2nd ed. Approved Standard M24-A2 Wayne, PA, USA: NCCLS; 2011
YoshidaS,
ArikawaK,
TsuyuguchiK,
KurashimaA,
HaradaT et al. Investigation of the population structure of Mycobacterium abscessus complex strains using 17-locus variable number tandem repeat typing and the further distinction of Mycobacterium massiliense hsp65 genotypes. J Med Microbiol2015; 64:254–261 [View Article][PubMed]
CohenT,
WilsonD,
WallengrenK,
SamuelEY,
MurrayM.
Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol2011; 49:385–388 [View Article][PubMed]
van IngenJ,
BoereeMJ,
van SoolingenD,
MoutonJW.
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat2012; 15:149–161 [View Article][PubMed]
BryantJM,
GrogonoDM,
GreavesD,
FowerakerJ,
RoddickI et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet2013; 381:1551–1560 [View Article][PubMed]